News/ News/ Oncology/ Top stories FDA starts quick review of Astellas/Seattle Genetics’ bladder cancer drug Phil Taylor antibody-drug conjugate, Astellas, bladder cancer, enfortumab vedotin, Seattle Genetics 0 Comment The FDA has started a priority review of Seattle Genetics and Astellas’ antibody-drug conjugate enfortumab vedotin in bladder Share X FDA starts quick review of Astellas/Seattle Genetics’ bladder cancer drug https://pharmaphorum.com/news/fda-starts-quick-review-of-astellas-seattle-genetics-bladder-cancer-drug/